Naya McKinnon, MD
Rheumatology · Las Vegas, NVNPI 1841229929
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for rheumatology clinicians in NV, where the typical reported total is $1,800.
Across 32 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$107
- Johnson & Johnson$59
- PTC Therapeutics, Inc.$57
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$55
- Sarepta Therapeutics, Inc.$55
- Tanabe Pharma America, Inc.$44
- plus $286 from 12 others
What the payments were for
- Food & beverage$663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $107 |
| Johnson & Johnson | 2 | $59 |
| PTC Therapeutics, Inc. | 3 | $57 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $55 |
| Sarepta Therapeutics, Inc. | 3 | $55 |
| Tanabe Pharma America, Inc. | 2 | $44 |
| AstraZeneca | 2 | $43 |
| Boehringer Ingelheim | 2 | $35 |
| Biogen | 1 | $24 |
| Grifols USA, LLC | 1 | $22 |
| Amylyx Pharmaceuticals, Inc. | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Sandoz | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Novartis | 1 | $20 |
| Sanofi | 1 | $15 |
How this compares
$663 in reported general payments places this provider in the 35th percentile of 43 rheumatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 15 | $125,059 |
| OrenciaAbatacept | 11 | $59,390 |
| Hydroxychloroquine Sulfate | 33 | $1,865 |
| Leflunomide | 34 | $1,856 |
| MethotrexateMethotrexate Sodium | 64 | $1,442 |
| Prednisone | 60 | $583 |
| Folic Acid | 17 | $196 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Las Vegas
- Ewa OlechLas Vegas$287K
- Walter ChathamLas Vegas$197K
- George KellyLas Vegas$185K
- Nasim DaoudLas Vegas$109K
- William KimLas Vegas$16K
- Aida LoudyiLas Vegas$10K
- Tudor JianuLas Vegas$8K
- Khalil Ibrahim BourjiLas Vegas$7K
- Neil BraunsteinLas Vegas$6K
- Michael CliffordLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.